The global infectious disease diagnostics market size is projected to reach USD 39.8billion by 2026 from USD 28.1billion in 2021, at a CAGR of 7.2% during the forecast period. Market growth is driven by factors such as global prevalence of infectious diseases & onset of COVID-19 and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements. On the other hand, an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the coming years.
The reagents, kits, and consumablesaccounted for the highest growth rate in theinfectious disease diagnostics market, byproduct& service, during the forecast period The infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services.The reagents, kits, and consumables segment accounted for the highest growth rate in the infectious disease diagnostics market in 2020.
The requirement of reagents, kits and consumables in large numbers compared to instrumentsis the main factor contributing to this segment’s high growth rate. This segment’s market growth can also be attributed to repeat purchases of reagents, kits, and consumables compared to instruments.
HAIs segment accounted for the highest CAGR Based on the disease type, the infectious disease diagnostics market is segmented into COVID-19, HIV, HAIs, hepatitis, CT/NG, HPV, TB, influenza, and other infectious diseases.The increasing number of cases and the availability of many COVID-19 diagnostic tests are driving the growth of this market.
In 2020, the HAIs segment accounted for the highest CAGR.
Diagnostic Laboratoriessegment accounted for the highest CAGR Based on end-users, the infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users.In 2020, the diagnostic laboratories segment accounted for the highest CAGR.
This can be attributed to increased test volume of infectious diseases and strengthening healthcare infrastructure for efficient disease diagnosis and treatment.
Asia Pacific: The fastest-growing regioninfectious disease diagnostics market The global infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.The Asia Pacific region is projected to register the highest CAGR during the forecast period.
Factors such as government efforts to increase awareness about the early detection of diseases and regular health check-ups, continuously rising healthcare expenditure, increasing number of hospitals, clinical diagnostic laboratories in India and China, and strengthening research base for diagnostic procedures across India, China, and Japan are driving the growth of the infectious disease diagnosticsmarket in this region.
The primary interviews conducted for this report can be categorized as follows: • By Company Type: Tier 1 - 20%, Tier 2 - 45%,and Tier 3 -35% • By Designation: C-level - 30%, D-level - 20%, and Others - 50% • By Region: North America -36%, Europe - 25%, Asia Pacific - 27%, Latin America – 9%, and the Middle East & Africa – 3%
Lits of Companies Profiled in the Report: • Abbott Laboratories (US) • F. Hoffmann-La Roche Ltd. (Switzerland) • bioMérieux SA (France) • Thermo Fisher Scientific Inc. (US) • Danaher Corporation (US) • QuidelCorporation(US) • Hologic, Inc. (US) • PerkinElmer Inc. (US) • Bio-Rad Laboratories, Inc. (US) • QIAGEN (Netherlands) • Siemens Healthineers AG (Germany) • Becton, Dickinson and Company (US) • DiaSorin S.p.A (Italy) • Grifols S.A. (Spain) • Sysmex Corporation (Japan) • Ortho Clinical Diagnostics (US) • Genetic Signatures (Australia) • Luminex Corporation (US) • Meridian Bioscience (US) • OraSure Technologies (US) • Trinity Biotech Plc. (Ireland) • Chembio Diagnostic Systems, Inc. (US) • Seegene Inc. (South Korea) • Co-Diagnostics, Inc. (US) • ELITechGroup (France) • Epitope Diagnostics, Inc. (US) • Trivitron Healthcare (India) • Meril Life Sciences Pvt. Ltd. (India) • InBios International, Inc. (US) • ABACUS Diagnostica Oy (Finland)
Research Coverage: This report provides a detailed picture of the global infectious disease diagnostics market.It aims at estimating the size and future growth potential of the market across different segments, such as product& service, test of testing, technology,disease type, end user, and region.
The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.
Our reports have been used by over 10K customers, including:
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
Anatomic pathology market to register a CAGR of 7.1% from 2020 to 2025. The global anatomic pathology market size is projected to reach a value of USD 46.8 billion by 2025 from USD 33.3 billion in 2020, at a CAGR of 7.1% during the forecast period. The growth in this market is attributed to the high incidence of cancer...
Anatomic pathology track and trace solutions market projected to grow at a CAGR of 10.4% The anatomic pathology track and trace solutions market is projected to reach USD 695.7 million by 2023 from USD 424.2 million in 2018, at a CAGR of 10.4% from 2018 to 2023. The increasing volume of diagnostic tests performed in anatomic...
With a population of more than 1 billion, China is the worldâ€™s largest country and therefore also its single largest potential market for goods and services. In the past ten years, China has led all major world economies in the average rate of growth in real GDP, total health expenditures, and government health expenditures. As an in vitro...
In Vitro Diagnostics
Point Of Care Testing
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.